Download PDF
Thromb Haemost 1980; 44(01): 035-038
DOI: 10.1055/s-0038-1650076
Original Article
Schattauer GmbH Stuttgart

Coagulation Abnormalities in Dogs with Neoplastic Disease

Bruce R Madewell
The Departments of Surgery and Clinical Pathology, University of California, School of Veterinary Medicine, Davis, California, U.S.A.
,
Bernard F Feldman
The Departments of Surgery and Clinical Pathology, University of California, School of Veterinary Medicine, Davis, California, U.S.A.
,
Sharron O’Neill
The Departments of Surgery and Clinical Pathology, University of California, School of Veterinary Medicine, Davis, California, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 27 February 1980

Accepted 23 June 1980

Publication Date:
13 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Conventional laboratory methods were used to screen untreated tumor-bearing dogs for hemostatic abnormalities. Excluded from study were dogs with clinical evidence of bleeding. The primary site for neoplastic disease in 100 dogs studied included hemolymphatic system, skin, bone, thyroid gland, oropharynx, mammary gland, and nasal cavity.

Eighty-three percent of the dogs had one or more abnormal coagulation tests. Thrombocytopenia occurred in 36 dogs and 3 had thrombocytosis. Twenty-five dogs had hypofibrinogenemia, and 25 had hyperfibrinogenemia. There were 32 dogs with prolongation of the activated partial thromboplastin time, 10 dogs with shortened prothrombin time, and 6 dogs with prolongation of the thrombin time. Sixteen dogs had positive protamine sulfate (paracoagulation) reaction, and 8% had increased plasma fibrin degradation products. The euglobulin lysis time was accelerated in 24% of the dogs, and 15% had schistocytes on blood film.

These data indicate that the majority of dogs with advanced neoplasms are likely to have abnormal coagulation tests.

Key words

Canine neoplasms - Coagulation abnormalities
 

  • References

  • 1 Rasche H, Dietrich M. Hemostatic abnormalities associated with malignant diseases. Eur J Cancer 1977; 13: 1053-1064
    CrossrefPubMedGoogle Scholar
  • 2 Merskey C. Pathogenesis and treatment of altered blood coagulability in patients with malignant tumors. Ann NY Acad Sci 1974; 230: 289-293
    CrossrefPubMedGoogle Scholar
  • 3 Sun NC J, Bowie EJ, Kazmier FJ, Elveback LR, Owen CA. Blood coagulation studies in patients with cancer. Mayo Clin Proc 1974; 49: 636-641
    PubMedGoogle Scholar
  • 4 Rasche H, Hoelzer D, Dietrich M, Keller A. Hemostatic defects in experimental leukemia. Haemostasis 1974; 3: 46-54
    PubMedGoogle Scholar
  • 5 Greene CE. Disseminated intravascular coagulation in the dog: a review. J Amer Anim Hosp Assoc 1975; 11: 674-686
    PubMedGoogle Scholar
  • 6 MacEwen EG, Hurvitz AI, Hayes A. Hyperviscosity syndrome associated with lymphocytic leukemia in three dogs. J Am Vet Med Assoc 1977; 170: 1309-1312
    PubMedGoogle Scholar
  • 7 Prasse KW, Hoskins JD, Glock RD, Kelso GA. Factor V deficiency and thrombocytopenia in a dog with adenocarcinoma. J Am Vet Med Assoc 1972; 160: 204-211
    PubMedGoogle Scholar
  • 8 Shepard VJ, Dodds-Laffin RJ. Gamma A myeloma in a dog with defective hemostasis. J Am Vet Med Assoc 1972; 160: 1121-1127
    PubMedGoogle Scholar
  • 9 Slappendel RJ, Rijnberk A, Van Arkel C. Spontaneous consumption coagulopathy in a dog with thyroid cancer. Thromb Diath Haemorrh 1970; 24: 129-135
    PubMedGoogle Scholar
  • 10 World Health Organization Report of the Second Consultation on the Biological Behavior and Therapy of Tumours of Domestic Animals, Geneva, March 13-15, 1979
    PubMed
  • 11 Bull B, Schneidermann M, Brecher G. Platelet counts with the Coulter counter. Am J Clin Path 1975; 44: 678-688
    PubMedGoogle Scholar
  • 12 Quick AJ, Stanley-Brown M, Bancroft EW. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935; 190: 501-511
    CrossrefPubMedGoogle Scholar
  • 13 Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. Am J Clin Path 1961; 36: 212-219
    CrossrefPubMedGoogle Scholar
  • 14 Jim RI S. A study of the plasma thrombin time. J Lab Clin Med 1957; 50: 45-60
    PubMedGoogle Scholar
  • 15 Lewis JH, Didisheim P. Differential diagnosis and treatment of hemorrhagic disease. Arch Int Med 1957; 100: 157-168
    CrossrefPubMedGoogle Scholar
  • 16 Owen CA, Bowie EJ W, Thompson JH. The Diagnosis of Bleeding Disorders. Second Edition. Boston, Little, Brown and Co.: 1975: 134-135
    Google Scholar
  • 17 Garvey MB, Black JM. The detection of fibrinogen/fibrin degradation products by means of a new antibody-coated latex particle. J Clin Path 1972; 25: 680-682
    CrossrefPubMedGoogle Scholar
  • 18 Niewiarowski S, Gurewich V. Laboratory identification of intravascular coagulation. J Lab Clin Med 1971; 77: 665-676
    PubMedGoogle Scholar
  • 19 Chakrabarti R, Bielawiec M, Evans JF, Fearnley GR. Methodological study and a recommended technique for determining the euglobulin lysis time. J Clin Path 1968; 21: 698-701
    CrossrefPubMedGoogle Scholar
  • 20 Sun NC J, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Am J Clin Path 1979; 71: 10-16
    CrossrefPubMedGoogle Scholar
  • 21 Schalm OW, Jain NC, Carrol EJ. Veterinary Hematology. 3rd Edition. Lea & Febiger, Philadelphia, Pa: 1975. pp. 554-555
    Google Scholar
  • 22 Dungworth DL, Goldman M, Switzer JW, McKelvie DH. Development of a myeloproliferative disorder in beagles continously exposed to 90Sr. Blood 1969; 34: 610-632
    PubMedGoogle Scholar
  • 23 Jain NC, Madewell BR, Weller RE, Geissler MC. Clinicopathologic findings and cytochemical characterization of myelomonocytic leukemia in five dogs. J Comp Path 1980 in press
    PubMedGoogle Scholar
  • 24 Al-Mondhiry H. Disorders of hemostasis in acute leukemia: Part II. Clin Bull 1975; 5: 51-56
    PubMedGoogle Scholar
  • 25 Schalm OW. Plasma protein: fibrinogen ratios in disease in the dog and horse – part EL. California Vet 1970; 24: 6-9
    PubMedGoogle Scholar
  • 26 Zimmerman TS, Fierer J, Rothberger H. Blood coagulation and the inflammatory response. Semin Hematol 1977; 14: 391-408
    PubMedGoogle Scholar
  • 27 Poggi A, Polentarutti N, Donati MB, De Gaetano G, Garattini S. Blood coagulation changes in mice bearing Lewis lung carcinoma, a metastasizing tumor. Cancer Res 1977; 37: 272-277
    PubMedGoogle Scholar
  • 28 Arkin CF, Hartman AS. The hypercoagulability states. Crit Rev Clin Lab Sci 1979; 10: 397-429
    CrossrefPubMedGoogle Scholar
  • 29 Hirsh J. Hypercoagulability. Semin Hematol 1977; 14: 409-425
    PubMedGoogle Scholar
  • 30 Hougie C. Euglobulin lysis time. In: Williams WJ, Beutler E, Erslev AJ, Rundles RW. (eds.) Hematology, Second edition. McGraw Hill, New York: 1977. pp. 1654
    Google Scholar
  • 31 Antman KH, Skarin AT, Mayer RJ, Hargreaves HK, Canellos GP. Microangiopathic hemolytic anemia and cancer: A review. Medicine 1979; 58: 377-384
    CrossrefPubMedGoogle Scholar